Evidence map›Paper›PMID 39381032›Full record

ArticleFrontiers in nuclear medicine2024

Performance of simplified methods for quantification of [

Ruben Daniel de Ruiter, Esmée Botman, Bernd P Teunissen, Adriaan Anthonius Lammertsma, Ronald Boellaard, Pieter G Raijmakers, Lothar A Schwarte, Jakko A Nieuwenhuijzen, Dinko Gonzalez Trotter, Elisabeth Marelise W Eekhoff and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03188666 (A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03188666 phase2completednot on this map

A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2018 to 2021Enrolled44ConditionsFibrodysplasia Ossificans ProgressivaArmsREGN2477, Matching placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Na[EJNMMI research · 2025
    Article
  2. [Biomolecules · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruben Daniel de RuiterDepartment of Internal Medicine, Endocrinology Section, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Esmée BotmanDepartment of Internal Medicine, Endocrinology Section, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Bernd P TeunissenDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Adriaan Anthonius LammertsmaDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Pieter G RaijmakersDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Lothar A SchwarteDepartment of Anesthesiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Jakko A NieuwenhuijzenDepartment of Urology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Dinko Gonzalez TrotterRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Elisabeth Marelise W EekhoffDepartment of Internal Medicine, Endocrinology Section, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Maqsood YaqubDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, genetic disease in which heterotopic bone is formed in muscles, tendons and ligaments throughout the body. Disease progression is variable over time and between individuals. Results: Seven patients (age range: 20-31 years) with FOP underwent dynamic [ Conclusion: The present data supports the use of TBR for assessing fluoride uptake in PET-active lesions in FOP. Clinical trial registration: Sub-study of the Lumina-1 trial (clinicaltrials.gov, NCT03188666, registered 13-06-2017).

Indexed as

[18F]NaFdynamic imagingfibrodysplasia ossificans progressivaPETpositron emission tomographysodiumfluoride

Identifiers

PMID39381032
PMCPMC11460293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.